Differential β-arrestin - Dependent conformational signaling and cellular responses revealed by angiotensin analogs

Science Signaling

Volumn 5, Issue 221, 2012, Pages

  Zimmerman, Brandon ^a,b   Beautrait, Alexandre ^c   Aguila, Benjamin ^a   Charles, Ricardo ^d   Escher, Emanuel ^e   Claing, Audrey ^d   Bouvier, Michel ^c   Laporte, Stéphane A ^a,b  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN DERIVATIVE; BETA ARRESTIN; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; ANGIOTENSIN II; DRUG DERIVATIVE; MAPK1 PROTEIN, HUMAN; MULTIPROTEIN COMPLEX; RETINA S ANTIGEN;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL MIGRATION; CELL PROLIFERATION; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ENDOSOME; ENZYME ACTIVATION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STABILITY; RAT; RECEPTOR BINDING; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; ANIMAL; CATTLE; CELL STRAIN HEK293; DRUG EFFECT; GENETICS; METABOLISM; PHYSIOLOGY;

ANGIOTENSIN II; ANIMALS; ARRESTINS; CATTLE; ENDOSOMES; HEK293 CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MULTIPROTEIN COMPLEXES; PROTEIN CONFORMATION; RECEPTOR, ANGIOTENSIN, TYPE 1;

EID: 84860253205     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2002522     Document Type: Article

References (49)

1. N. Basso, R. Cini, A. Pietrelli, L. Ferder, N. A. Terragno, F. Inserra, Protective effect of long-term angiotensin II inhibition. Am. J. Physiol. Heart Circ. Physiol. 293, H1351-H1358 (2007).
2. S. Rajagopalan, S. Kurz, T. Münzel, M. Tarpey, B. A. Freeman, K. K. Griendling, D. G. Harrison, Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J. Clin. Invest. 97, 1916-1923 (1996).
3. S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, G. Dagenais, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342, 145-153 (2000).
4. P. K. Mehta, K. K. Griendling, Angiotensin II cell signaling: Physiological and pathological effects in the cardiovascular system. Am. J. Physiol. Cell Physiol. 292, C82-C97 (2007).
5. 2-adrenergic receptor and rhodopsin systems. J. Biol. Chem. 267, 8558-8564 (1992).
6. S. M. DeWire, S. Ahn, R. J. Lefkowitz, S. K. Shenoy, β-Arrestins and cell signaling. Annu. Rev. Physiol. 69, 483-510 (2007).
7. 2+/ calmodulin-dependent transactivation of epidermal growth factor receptor. Circ. Res. 82, 1338-1348 (1998).
8. K. Rakesh, B. Yoo, I. M. Kim, N. Salazar, K. S. Kim, H. A. Rockman, β-Arrestin - biased agonism of the angiotensin receptor induced by mechanical stress. Sci. Signal. 3, ra46 (2010).
9. D. Gesty-Palmer, M. Chen, E. Reiter, S. Ahn, C. D. Nelson, S. Wang, A. E. Eckhardt, C. L. Cowan, R. F. Spurney, L. M. Luttrell, R. J. Lefkowitz, Distinct β-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J. Biol. Chem. 281, 10856-10864 (2006).
10. S. Galandrin, G. Oligny-Longpre, H. Bonin, K. Ogawa, C. Gales, M. Bouvier, Conformational rearrangements and signaling cascades involved in ligand-biased mitogenactivated protein kinase signaling through the β1-adrenergic receptor. Mol. Pharmacol. 74, 162-172 (2008).
11. S. Galandrin, M. Bouvier, Distinct signaling profiles of β1 and β2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol. Pharmacol. 70, 1575-1584 (2006).
12. M. Azzi, P. G. Charest, S. Angers, G. Rousseau, T. Kohout, M. Bouvier, G. Pineyro, β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc. Natl. Acad. Sci. U.S.A. 100, 11406-11411 (2003).
13. J.W.Wisler, S. M. DeWire, E. J. Whalen, J. D. Violin, M. T. Drake, S. Ahn, S. K. Shenoy, R. J. Lefkowitz, A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling. Proc. Natl. Acad. Sci. U.S.A. 104, 16657-16662 (2007).
14. M. T. Drake, J. D. Violin, E. J. Whalen, J. W. Wisler, S. K. Shenoy, R. J. Lefkowitz, β-Arrestin-biased agonism at the β2-adrenergic receptor. J. Biol. Chem. 283, 5669-5676 (2008).
15. S. Rajagopal, S. Ahn, D. H. Rominger,W. Gowen-MacDonald, C. M. Lam, S. M. DeWire, J. D. Violin, R. J. Lefkowitz, Quantifying ligand bias at seven-transmembrane receptors. Mol. Pharmacol. 80, 367-377 (2011).
16. 256 of AT1 receptor in agonist activation. J. Biol. Chem. 270, 28511-28514 (1995).
17. A. C. Holloway, H. Qian, L. Pipolo, J. Ziogas, S. Miura, S. Karnik, B. R. Southwell, M. J. Lew, W. G. Thomas, Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. Mol. Pharmacol. 61, 768-777 (2002).
18. Y. Yamano, K. Ohyama, S. Chaki, D. F. Guo, T. Inagami, Identification of amino acid residues of rat angiotensin II receptor for ligand binding by site directed mutagenesis. Biochem. Biophys. Res. Commun. 187, 1426-1431 (1992).
19. S. Ahn, S. K. Shenoy, H. Wei, R. J. Lefkowitz, Differential kinetic and spatial patterns of β-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J. Biol. Chem. 279, 35518-35525 (2004).
20. J. D. Violin, S. M. DeWire, D. Yamashita, D. H. Rominger, L. Nguyen, K. Schiller, E. J. Whalen, M. Gowen, M. W. Lark, Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J. Pharmacol. Exp. Ther. 335, 572-579 (2010).
21. q/protein kinase Cζ pathways for ERK stimulated by angiotensin type 1A receptors in vascular smooth muscle cells converge on transactivation of the epidermal growth factor receptor. J. Biol. Chem. 284, 11953-11962 (2009).
22. M. M. Bonde, J. T. Hansen, S. J. Sanni, S. Haunsø, S. Gammeltoft, C. Lyngsø, J. L. Hansen, Biased signaling of the angiotensin II type 1 receptor can be mediated through distinct mechanisms. PLoS One 5, e14135 (2010).
23. K. Xiao, J. Sun, J. Kim, S. Rajagopal, B. Zhai, J. Villén, W. Haas, J. J. Kovacs, A. K. Shukla, M. R. Hara, M. Hernandez, A. Lachmann, S. Zhao, Y. Lin, Y. Cheng, K. Mizuno, A. Ma'ayan, S. P. Gygi, R. J. Lefkowitz, Global phosphorylation analysis of β-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc. Natl. Acad. Sci. U.S.A. 107, 15299-15304 (2010).
24. K. Rajagopal, E. J. Whalen, J. D. Violin, J. A. Stiber, P. B. Rosenberg, R. T. Premont, T. M. Coffman, H. A. Rockman, R. J. Lefkowitz, β-Arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc. Natl. Acad. Sci. U.S.A. 103, 16284-16289 (2006).
25. G. Boerrigter, M. W. Lark, E. J. Whalen, D. G. Soergel, J. D. Violin, J. C. Burnett Jr., Cardiorenal actions of TRV120027, a novel β-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: A novel therapeutic strategy for acute heart failure. Circ. Heart Fail. 4, 770-778 (2011).
26. P. G. Charest, S. Terrillon, M. Bouvier, Monitoring agonist-promoted conformational changes of β-arrestin in living cells by intramolecular BRET. EMBO Rep. 6, 334-340 (2005).
27. J. Kim, S. Ahn, X. R. Ren, E. J. Whalen, E. Reiter, H. Wei, R. J. Lefkowitz, Functional antagonism of different G protein-coupled receptor kinases for β-arrestin-mediated angiotensin II receptor signaling. Proc. Natl. Acad. Sci. U.S.A. 102, 1442-1447 (2005).
28. J. W. Black, P. Leff, Operational models of pharmacological agonism. Proc. R. Soc. Lond. B Biol. Sci. 220, 141-162 (1983).
29. T. Kenakin, A. Christopoulos, Analytical pharmacology: The impact of numbers on pharmacology. Trends Pharmacol. Sci. 32, 189-196 (2011).
30. V. Gousseva, M. Simaan, S. A. Laporte, P. S. Swain, Inferring the lifetime of endosomal protein complexes by fluorescence recovery after photobleaching. Biophys. J. 94, 679-687 (2008).
31. B. Aguila, M. Simaan, S. A. Laporte, Study of G protein-coupled receptor/β-arrestin interactions within endosomes using FRAP. Methods Mol. Biol. 756, 371-380 (2011).
32. H. Wei, S. Ahn, S. K. Shenoy, S. S. Karnik, L. Hunyady, L. M. Luttrell, R. J. Lefkowitz, Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc. Natl. Acad. Sci. U.S.A. 100, 10782-10787 (2003).
33. C. M. Godin, S. S. Ferguson, The angiotensin II type 1 receptor induces membrane blebbing by coupling toRhoA,Rho kinase, andmyosin light chain kinase.Mol.Pharmacol. 77, 903-911 (2010).
34. W. R. Huckle, H. S. Earp, Regulation of cell proliferation and growth by angiotensin II. Prog. Growth Factor Res. 5, 177-194 (1994).
35. A. K. Shukla, J. D. Violin, E. J. Whalen, D. Gesty-Palmer, S. K. Shenoy, R. J. Lefkowitz, Distinct conformational changes in β-arrestin report biased agonism at seventransmembrane receptors. Proc. Natl. Acad. Sci. U.S.A. 105, 9988-9993 (2008).
36. 2- adrenergic receptor establish a barcode that encodes differential functions of β-arrestin. Sci. Signal. 4, ra51 (2011).
37. A. Aumelas, C. Sakarellos, K. Lintner, S. Fermandjian, M. C. Khosla, R. R. Smeby, F. M. Bumpus, Studies on angiotensin II and analogs: Impact of substitution in position 8 on conformation and activity. Proc. Natl. Acad. Sci. U.S.A. 82, 1881-1885 (1985).
38. M. de Gasparo, K. J. Catt, T. Inagami, J. W. Wright, T. Unger, International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 52, 415-472 (2000).
39. B. Zimmerman, M. Simaan, M. H. Lee, L. M. Luttrell, S. A. Laporte, c-Src-mediated phosphorylation of AP-2 reveals a general mechanism for receptors internalizing through the clathrin pathway. Cell. Signal. 21, 103-110 (2009).
40. E. Goupil, D. Tassy, C. Bourguet, C. Quiniou, V. Wisehart, D. Pétrin, C. Le Gouill, D. Devost, H. H. Zingg, M. Bouvier, H. U. Saragovi, S. Chemtob, W. D. Lubell, A. Claing, T. E. Hébert, S. A. Laporte, A novel biased allosteric compound inhibitor of parturition selectively impedes the prostaglandin F2a-mediated Rho/ROCK signaling pathway. J. Biol. Chem. 285, 25624-25636 (2010).
41. B. Zimmerman, M. Simaan, M. Y. Akoume, N. Houri, S. Chevallier, P. Séguéla, S. A. Laporte, Role of barrestins in bradykinin B2 receptor-mediated signalling. Cell. Signal. 23, 648-659 (2011).
42. M. Leduc, B. Breton, C. Gales, C. Le Gouill, M. Bouvier, S. Chemtob, N. Heveker, Functional selectivity of natural and synthetic prostaglandin EP4 receptor ligands. J. Pharmacol. Exp. Ther. 331, 297-307 (2009).
43. B. Breton, É. Sauvageau, J. Zhou, H. Bonin, C. Le Gouill, M. Bouvier, Multiplexing of multicolor bioluminescence resonance energy transfer. Biophys. J. 99, 4037-4046 (2010).
44. D. Fessart, M. Simaan, S. A. Laporte, c-Src regulates clathrin adapter protein 2 interaction with β-arrestin and the angiotensin II type 1 receptor during clathrin-mediated internalization. Mol. Endocrinol. 19, 491-503 (2005).
45. S. A. Laporte, G. Servant, D. E. Richard, E. Escher, G. Guillemette, R. Leduc, The tyrosine within the NPXnY motif of the human angiotensin II type 1 receptor is involved in mediating signal transduction but is not essential for internalization. Mol. Pharmacol. 49, 89-95 (1996).
46. C. Koole, D. Wootten, J. Simms, C. Valant, R. Sridhar, O. L. Woodman, L. J. Miller, R. J. Summers, A. Christopoulos, P. M. Sexton, Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: Implications for drug screening. Mol. Pharmacol. 78, 456-465 (2010).
47. K. D. Pfleger, K. A. Eidne, Illuminating insights into protein-protein interactions using bioluminescence resonance energy transfer (BRET). Nat. Methods 3, 165-174 (2006).
48. F. F. Hamdan, Y. Percherancier, B. Breton, M. Bouvier, Monitoring protein-protein interactions in living cells by bioluminescence resonance energy transfer (BRET), in Current Protocols in Neuroscience (John Wiley & Sons Inc., New York, 2006).
49. M. Cotton, P. L. Boulay, T. Houndolo, N. Vitale, J. A. Pitcher, A. Claing, Endogenous ARF6 interacts with Rac1 upon angiotensin II stimulation to regulate membrane ruffling and cell migration. Mol. Biol. Cell 18, 501-511 (2007).